Neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer
Disease site: Breast cancer
Treatment modality: Combination therapy
Neocent is a multi-centre randomised, parallel group, comparative phase III neo-adjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with strongly ER positive primary breast cancer in whom it is felt cytoreductive pre-operative systemic therapy is indicated.
Neoadjuvant chemotherapy is a standard of care for down-staging of breast cancer pre-operatively. However, aromatase inhibitors (AIs) also have activity in this setting in postmenopausal women with oestrogen receptor (ER) positive breast cancer (Eiermann et al., 2001). In strongly ER positive breast cancer, chemotherapy efficacy is reduced, whereas, the efficacy of AIs appears greatest and it is unclear which treatment response is more efficacious.
Overall, 70% of breast cancers are ER positive, and in postmenopausal women 85% of these are strongly ER positive (Ellis M, 2003). This study will help clarify optimal treatment for this patient group.
The study is divided into two phases, a pilot phase and a main efficacy phase. The aim of the pilot study is to assess the feasibility of patient recruitment and tissue collection for a subsequent ‘main study’. The pilot study requires 20 patients per treatment group.
This is an International Collaborative Cancer Group trial (ICCG) (C/21/07).
Chief Investigator: Professor R. C. Coombes, Imperial College, London
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: Please see the ICCG Necent webpage
Sponsor: Imperial College London
Funding: Cancer Research UK (C37/A9356), Novartis
Further information on the Neocent trial may be found on the ICCG Necent webpage